OMMH Stock Overview
Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Omnimmune Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000067 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.44% |
| 5 Year Change | -98.04% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| OMMH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -4.5% | -1.1% |
| 1Y | n/a | 3.4% | 25.8% |
Return vs Industry: Insufficient data to determine how OMMH performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how OMMH performed against the US Market.
Price Volatility
| OMMH volatility | |
|---|---|
| OMMH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OMMH has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OMMH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a |
Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, which target a hormone called human chorionic gonadotropin.
Omnimmune Holdings, Inc. Fundamentals Summary
| OMMH fundamental statistics | |
|---|---|
| Market cap | US$980.00 |
| Earnings (TTM) | -US$1.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs OMMH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMMH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.79m |
| Earnings | -US$1.79m |
Last Reported Earnings
Sep 30, 2010
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did OMMH perform over the long term?
See historical performance and comparison